A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
Public ClinicalTrials.gov record NCT05828589. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of Bcl-2 Inhibitor BGB-21447 in Patients With Mature B-Cell Malignancies
Study identification
- NCT ID
- NCT05828589
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 112 participants
Conditions and interventions
Conditions
- Refractory Chronic Lymphocytic Leukemia
- Refractory Diffuse Large B-cell Lymphoma
- Refractory Follicular Lymphoma
- Refractory Marginal Zone Lymphoma
- Refractory Non-Hodgkin Lymphoma
- Refractory Small Lymphocytic Lymphoma
- Relapse Diffuse Large B Cell Lymphoma
- Relapsed Chronic Lymphocytic Leukemia
- Relapsed Follicular Lymphoma
- Relapsed Marginal Zone Lymphoma
- Relapsed Non-Hodgkin Lymphoma
- Relapsed Small Lymphocytic Lymphoma
- Richter Transformation
- Transformed Non-Hodgkin Lymphoma
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 19, 2023
- Primary completion
- Apr 30, 2026
- Completion
- Apr 30, 2026
- Last update posted
- Mar 11, 2026
2023 – 2026
United States locations
- U.S. sites
- 7
- U.S. states
- 5
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sibley Memorial Hospital Johns Hopkins Medicine | Washington D.C. | District of Columbia | 20016 | — |
| University of Iowa Hospitals and Clinics | Iowa City | Iowa | 52242-1009 | — |
| Mission Cancer and Blood | Waukee | Iowa | 50263 | — |
| Sidney Kimmel Comprehensive Cancer At Johns Hopkins | Baltimore | Maryland | 21287 | — |
| Nyu Langone Health Perlmutter Cancer Center At Nyu Langone Hospital Long Island | Mineola | New York | 11501 | — |
| Laura and Isaac Perlmutter Cancer Center At Nyu Langone Health | New York | New York | 10016-2708 | — |
| Avera Cancer Institute | Sioux Falls | South Dakota | 57105-2108 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
Recently updated Refractory Chronic Lymphocytic Leukemia trials
Other public records listing Refractory Chronic Lymphocytic Leukemia. Sorted by last update posted; newest first. Not a recommendation.
- NCT04195633: Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies Recruiting
- NCT07061951: Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia Recruiting
- NCT05418088: Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies Recruiting
- NCT04941716: Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial Recruiting
- NCT02160015: Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery Active, not recruiting
- NCT03479268: Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05828589, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 11, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05828589 live on ClinicalTrials.gov.